Imugene Ltd

IMU

Company Profile

  • Business description

    Imugene Ltd specializes in a clinical-stage immuno-oncology company. Its products include HER-Vaxx, PD1-Vaxx, CF33 and CF33 CD19. HER-Vaxx is a proprietary HER2 +ve cancer vaccine that stimulates a polyclonal antibody response to HER2/neu. The company is also developing B-cell peptide cancer vaccines and therapeutics. Its only operating segment is the Research and Development of oncolytic immunotherapies.

  • Contact

    4-6 Bligh Street
    Suite 12.01, Level 12
    SydneyNSW2000
    AUS

    https://www.imugene.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    30 June 2025

    Employees

    5

Stocks News & Analysis

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,175.1049.900.61%
CAC 407,536.2633.480.45%
DAX 4022,242.45177.940.81%
Dow JONES (US)40,113.5020.100.05%
FTSE 1008,415.257.810.09%
HKSE21,980.7470.980.32%
NASDAQ17,382.94216.901.26%
Nikkei 22535,705.74666.591.90%
NZX 50 Index12,017.8461.370.51%
S&P 5005,525.2140.440.74%
S&P/ASX 2007,968.2047.700.60%
SSE Composite Index3,295.062.23-0.07%

Market Movers